Methods and related compositions for the treatment of cancer
Abstract
Disclosed herein are compositions and nanoconjugates comprising a micelle construct; an antibody single chain fragment variable (scFv); a NF-kb inhibitor; and a topoisomerase II inhibitor. Further disclosed herein are methods of delivering a drug molecule to a tumor site of a subject comprising: attaching the drug molecule to a targeted micelle, wherein the targeted micelle comprises a micelle construct and an antibody single chain fragment variable (scFv); and delivering the drug molecule attached to the targeted micelle to the tumor site through intracellular delivery. Also disclosed herein are methods of treating cancer or inhibiting tumor cell growth comprising administering to a subject in need thereof, a therapeutically effective dosage of a composition comprising a micelle construct, an antibody single chain fragment variable (scFv), a NF-kb inhibitor, and a topoisomerase II inhibitor.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A composition comprising:
a. a micelle construct; b. an antibody single chain fragment variable (scFv); c. a NF-kb inhibitor; and d. a topoisomerase II inhibitor.
2 . The composition of claim 1 , wherein the scFv is conjugated to the micelle construct.
3 . The composition of claim 1 , wherein the micelle construct is conjugated to the NF-kb inhibitor.
4 . The composition of claim 1 , wherein the micelle construct is conjugated to the NF-kb inhibitor and the topoisomerase II inhibitor.
5 . The composition of claim 1 , wherein the NF-kb inhibitor is curcumin or a pharmaceutical equivalent, analog, derivative, and/or salt thereof.
6 . The composition of claim 1 , wherein the topoisomerase II inhibitor is dox or a pharmaceutical equivalent, analog, derivative, and/or salt thereof.
7 . The composition of claim 1 , wherein the scFv is a glut-1_1 or glut-1_2 scFv.
8 . The composition of claim 1 , wherein the micelle construct is targeted to bind to glut-1_1 and/or glut-1_2 scFv.
9 . The composition of claim 1 , wherein the composition forms a targeted micelle.
10 . The composition of claim 9 , wherein the molecular size of the targeted micelle is 30 nm or less.
11 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
12 . A method of delivering a drug molecule to a tumor site of a subject comprising:
a. attaching the drug molecule to a targeted micelle, wherein the targeted micelle comprises a micelle construct and an antibody single chain fragment variable (scFv); and b. delivering the drug molecule attached to the targeted micelle to the tumor site of the subject through intracellular delivery.
13 . The method of claim 12 , wherein the drug molecule comprises dox and/or curcumin or a pharmaceutical equivalent, analog, derivative, and/or salt thereof.
14 . The method of claim 12 , wherein the molecular size of the targeted micelle is 30 nm or less.
15 . The method of claim 12 , wherein the tumor is a doxorubicin-resistant tumor.
16 . The method of claim 12 , wherein the tumor is a brain tumor, an ovarian tumor, or a colon tumor.
17 . A nanoconjugate, comprising:
a. a micelle construct; b. an antibody single chain fragment variable (scFv); c. a NF-kb inhibitor; and d. a topoisomerase II inhibitor; and
wherein the micelle construct, the antibody single chain fragment variable (scFv), the NF-kb inhibitor, and the topoisomerase II inhibitor are conjugated to one another.
18 . The nanoconjugate of claim 17 , wherein the nanoconjugate has a molecular size between 20 nm and 50 nm.
19 . The nanoconjugate of claim 17 , wherein the nanoconjugate has a molecular size less than 20 nm.
20 . The nanoconjugate of claim 17 , wherein the nanoconjugate is enclosed by a micelle.Join the waitlist — get patent alerts
Track US2017035904A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.